United States Patent 10,022,344 (Napxrofen Sodium Softgel): Claim Scope, Landscape, and US Exclusivity Exposure
US Drug Patent 10,022,344 targets a specific naproxen sodium soft gelatin capsule fill formulation and closely related manufacturing and use claims. The independent claim scope is medium-narrow on composition but broad on capsule shell and excipient latitude. The landscape risk for competitors turns on whether a generic or branded follow-on can avoid the defined combination of (i) naproxen sodium, (ii) ~5% deionizing agent selected from specific short-chain acids, (iii) polyethylene glycol (PEG) in a defined range, and (iv) a solubilizer selected from defined solubilizers. The key engineering escape routes are either to substitute outside the claim’s deionizing agent or solubilizer selections, or to shift the formulation outside the stated weight ranges (PEG 10% to 80% and solubilizer 1% to 10%) while maintaining functional equivalence.
What is US Patent 10,022,344 claiming for naproxen sodium soft gelatin capsules?
Bottom line: The patent claims a softgel naproxen sodium composition defined by a four-component fill system plus optional excipients, with separate claim families for a liquid fill and for methods of treatment and manufacture.
Independent claim 1 (composition)
Claim 1 is a soft gelatin capsule with a fill material comprising:
- Naproxen sodium
- About 5% of a deionizing agent comprising acetic acid, propionic acid, pyruvic acid, or lactic acid
- Polyethylene glycol (PEG)
- A solubilizer comprising glycerin, polyvinylpyrrolidone (PVP), propylene glycol, or combinations
This is the core novelty anchor: a naproxen sodium softgel fill that couples a deionizing acid with PEG plus defined solubilizers.
Dependent claims 2-6 (fill tightening)
Claim 2 narrows deionizing agent to propionic acid or lactic acid. Claim 3 narrows further to lactic acid.
Claim 4 limits PEG to 10% to 80% by weight.
Claim 5 specifies PEG molecular weight 300 to 1500.
Claim 6 adds optional water 1% to 18% by weight.
Dependent claim 7 (excipient breadth)
Claim 7 allows the fill material to further comprise broadly described excipients: plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, bioavailability enhancers, solvents, dyes, preservatives, surfactants, or combinations. This is a meaningful scope expansion: it permits reformulation around the core four components.
Dependent claims 8-9 (solubilizer range and liquid fill)
Claim 8 requires solubilizer amount 1% to 10% by weight.
Claim 9 requires the fill material is liquid.
Method claims 10 and 11-12 (use and manufacture)
Claim 10: administering the capsule of claim 1 to treat pain, inflammation, or fever.
Claim 11: method of making by mixing components (the claim 1-defined components) and encapsulating in a softgel capsule.
Claim 12 adds a manufacturing temperature of 50°C to 70°C for step (a).
Claims 13-20 (second composition set with explicit water)
Claims 13-19 are parallel to claims 1-9 but explicitly include water as part of the fill material:
- Claim 13: fill includes naproxen sodium + about 5% deionizing agent from the same list + PEG + solubilizer from the same list + water
- Claim 14: PEG 10%-80%
- Claim 15: PEG MW 300-1500
- Claim 16: water 1%-18%
- Claim 17: optional excipients as in claim 7
- Claim 18: solubilizer 1%-10%
- Claim 19: liquid fill
Claim 20: method for treating pain/inflammation/fever by administering the claim 13 capsule.
How broad or narrow is claim scope under US 10,022,344?
Bottom line: Scope is moderately narrow on the defined acid and solubilizer selections and on PEG/solubilizer ranges, but broad on optional excipients and on capsule form factor (soft gelatin capsule).
Claim elements that create “hard boundaries”
These are the features most likely to determine infringement for composition and method claims:
- Naproxen sodium (must be present)
- Deionizing agent selection limited to: acetic, propionic, pyruvic, lactic acids
- Deionizing agent level is about 5%
- Solubilizer selection limited to: glycerin, PVP, propylene glycol, or combinations
- PEG is present (claim 4 and 5 define range and MW only in dependent claims)
- Solubilizer range 1% to 10% is a dependent narrowing element (claim 8/18)
- Water presence distinguishes claim set 13-19 from claim set 1-12; water is optional in claim 6 but required in claim 13/16
Claim elements that create “soft boundaries”
These can be satisfied by design-around unless the dependent claims are asserted:
- Optional excipients (claim 7/17) are extremely broad, which reduces freedom for a competitor only if the competitor’s excipient set triggers functional equivalence arguments. The language itself is permissive.
- Soft gelatin capsule: shell material is not deeply constrained beyond “soft gelatin,” so substitution to different capsule manufacturing technology could avoid shell identity arguments, but that is a product design choice.
Which alternatives are within the claims for deionizing agent and solubilizer?
Bottom line: The “selection list” for acids and solubilizers is narrow and therefore is the best compliance and design-around lever.
Deionizing agent list (claim 1 and 13)
- Acetic acid
- Propionic acid
- Pyruvic acid
- Lactic acid
All as about 5% in the fill material
Dependent narrowing:
- Claim 2: propionic acid or lactic acid
- Claim 3: lactic acid only
Solubilizer list (claim 1 and 13)
- Glycerin
- Polyvinylpyrrolidone (PVP)
- Propylene glycol
- Combinations thereof
Dependent narrowing:
- Claim 8 and 18: solubilizer 1% to 10% by weight
Does US 10,022,344 cover liquid-fill naproxen softgels with PEG?
Bottom line: Yes. Claim 9 and claim 19 explicitly require liquid fill, and the composition set is written for a softgel-compatible liquid formulation.
Liquid fill coverage
- Claim 9: fill material is liquid (for claim 1)
- Claim 19: fill material is liquid (for claim 13)
PEG and molecular weight (dependent narrowing)
- PEG amount 10%-80% (claims 4 and 14)
- PEG molecular weight 300-1500 (claims 5 and 15)
Even if a competitor uses PEG outside molecular weight 300-1500, they could still run into infringement on claim 1/13 if asserted independently. But dependent claims 4-5/14-15 create additional argument structure that can be used to contest scope if the independent claims are found invalid or if only dependent claims are asserted.
How do claims 1 vs 13 differ, and how does that affect infringement risk?
Bottom line: Claim 13 includes water as an explicit element, while claim 1 does not require water (water is optional via dependent claim 6).
Practical risk split
- If a competitor’s formulation includes water within 1%-18% and otherwise tracks the core elements, they risk both the base claim structure and the water-specific dependent claims.
- If a competitor avoids water (or uses water outside the 1%-18% dependent band), then claim 13/16 likely do not read, but claim 1 can still read because water is not required in claim 1 (and the “water” limitation is only in dependent claim 6).
What manufacturing and method-of-use scope does US 10,022,344 provide?
Bottom line: The patent adds leverage beyond formulation, including methods of manufacture (with temperature) and methods of treatment (pain/inflammation/fever).
Method of making (claim 11-12)
- Mixing components (a)-(d) as defined in claim 1 and encapsulating as a softgel capsule
- Dependent: mixing at 50°C to 70°C
For design-around, a competitor would need to avoid either:
- performing the claimed mixing of the exact component set, or
- mixing outside 50°C-70°C if that dependent claim is asserted.
Method of treatment (claims 10 and 20)
- Administering the claimed capsule to treat pain, inflammation, or fever
This is standard “medical use” scope and typically supports enforcement against those who sell and instruct use consistent with the claimed indication, though actual enforcement posture depends on how the drug is labeled and marketed.
How can competitors design around the claims for naproxen sodium softgels?
Bottom line: Most credible design-arounds target the deionizing acid and solubilizer selection, or shift deionizing level and PEG/solubilizer quantities to avoid dependent claim read-through.
Design-around levers by claim element
-
Change the deionizing agent
- Avoid acetic/propionic/pyruvic/lactic acids at “about 5%”
- Using another acid (or salt-based system) would aim to escape the literal selection list
-
Alter deionizing agent level away from “about 5%”
- Even within the same acid, moving concentration materially away from the “about 5%” band can be a path to avoid read-through
-
Change the solubilizer
- Avoid glycerin/PVP/propylene glycol combinations in the defined solubilizer role
-
Move PEG quantity or molecular weight
- Keep PEG outside 10%-80% or outside MW 300-1500 for avoiding dependent claims 4-5/14-15
- Note: independent claim 1/13 only says PEG is present, so moving outside dependent ranges mainly avoids dependent claims rather than necessarily avoiding the independent composition
-
Avoid water inclusion if targeting claim 13
- Remove water or incorporate it outside 1%-18% (dependent claims 16), though claim 1 can remain relevant
-
Manufacturing temperature
- If a temperature-based dependent claim is asserted, mixing outside 50°C-70°C is a potential avoidance approach
What does the patent’s structure imply for a Paragraph IV generic or follow-on softgel challenge?
Bottom line: A generic Paragraph IV challenge generally targets either:
- invalidity (e.g., obviousness, lack of written description/enablement, indefiniteness),
- non-infringement (formulation differences),
- or both.
Given the claim language, a generic’s non-infringement case would likely focus on:
- not meeting the ~5% deionizing agent limitation,
- not using the listed acid or listed solubilizer,
- using PEG outside specified dependent ranges (if dependent claims asserted),
- and/or not meeting water inclusion required by claim 13.
Orange Book status and US patent number alignment for 10,022,344
Bottom line: The prompt provides claim text but does not provide the Orange Book listing, listed drug product, NDA/ANDA/BLA number, or patent expiration date/approval date for 10,022,344. Without that linkage, the US regulatory exclusivity and launch timing analysis cannot be completed for this patent number.
How strong is the patent estate for this formulation concept?
Bottom line: Strength assessment depends on the breadth of the claim versus prior art. Based solely on claim language, the patent is enforceable on a specific composition architecture with defined selection lists and quantitative anchors. Strength is therefore likely to be driven by the presence (or absence) of prior art disclosing:
- naproxen sodium softgels using PEG and the specified deionizing acids, and
- the same solubilizer system in the same formulation roles, and
- achieving the claimed solubility or stability improvements.
Because the claim is specific, prior art must match key elements to threaten novelty. At the same time, the broad excipient language can make “combination obviousness” arguments easier for challengers, depending on how the deionizing agent and solubilizer selections were used in the art.
Key Takeaways
- US 10,022,344 claims a naproxen sodium soft gelatin capsule fill with a defined deionizing acid (~5%) plus PEG plus a defined solubilizer (glycerin/PVP/propylene glycol), with optional broad excipients.
- The most infringement-critical limitations are the acid selection list, the ~5% deionizing concentration, the solubilizer selection list, and the PEG/solubilizer ranges found in dependent claims.
- Claims 13-20 add water as an explicit element, creating a second formulation lane.
- Method claims cover mixing/encapsulation and treatment of pain/inflammation/fever, adding enforcement paths beyond just “making the capsule.”
FAQs
- Can a naproxen sodium softgel avoid US 10,022,344 by using a different acid deionizing agent than acetic/propionic/pyruvic/lactic acids?
- If PEG is used outside 300-1500 MW or outside 10%-80% by weight, does that avoid infringement or only dependent claims?
- Does including water automatically put a competitor into claim 13/16 territory, or does water amount need to fall within 1%-18%?
- How do the method-of-making temperature limits (50°C to 70°C) affect process design-around strategies?
- What labeling or patient-use factors influence enforcement of the method-of-use claims (pain, inflammation, fever)?
References
No sources were provided or cited in the prompt, and no Orange Book/NDA mapping, prosecution history, or expiration data was supplied for US Patent 10,022,344.
